Olfactory Dysfunction in ? Thalassemia Major Patients Treated With Iron-Chelating Agents

Basit Öğe Kaydı
dc.contributor.authorDerin, Serhan
dc.contributor.authorErdogan, Selvet
dc.contributor.authorSahan, Murat
dc.contributor.authorAzik, Mehmet Fatih
dc.contributor.authorDerin, Hatice
dc.contributor.authorTopal, Yasar
dc.contributor.authorTopal, Hatice
dc.date.accessioned2024-02-23T14:26:56Z
dc.date.available2024-02-23T14:26:56Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractOcular and ophthalmological adverse effects may be seen in beta-thalassemia major (BTM) patients treated with regular blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this population. In this study, we aimed to investigate olfactory dysfunction in patients with BTM and determine the etiological factors. A total of 43 patients with BTM were included in the study. Forty-three patients without any nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The iron-chelating agents used, their duration of use, as well as hemoglobin and ferritin levels of the BTM patients were recorded. Sniffin' Sticks test (SST) was used to assess olfactory functions, and BTM and control groups were compared for the results. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group had hyposmia while none of the patients in the control group had hyposmia (P < .001). Older age, low-hemoglobin level, and longer use of deferoxamine were found to be correlated with olfactory dysfunction. Olfactory dysfunction may be seen in BTM patients treated with iron-chelating agents. The results of this study suggest that screening for olfactory function may be needed in routine follow-up of BTM patients.en_US
dc.description.sponsorshipMugla Sitki Kocman University, Department of Scientific Research Projectsen_US
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Mugla Sitki Kocman University, Department of Scientific Research Projects.en_US
dc.identifier.doi10.1177/0145561319840079
dc.identifier.endpageNP130en_US
dc.identifier.issn0145-5613
dc.identifier.issn1942-7522
dc.identifier.issue8en_US
dc.identifier.pmid31142160en_US
dc.identifier.scopus2-s2.0-85066872502en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageNP125en_US
dc.identifier.urihttps://doi.org/10.1177/0145561319840079
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14376
dc.identifier.volume98en_US
dc.identifier.wosWOS:000490951400002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofEnt-Ear Nose & Throat Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBeta-Thalassemiaen_US
dc.subjectBlood Transfusionen_US
dc.subjectChelation Therapyen_US
dc.subjectOlfaction Disordersen_US
dc.titleOlfactory Dysfunction in ? Thalassemia Major Patients Treated With Iron-Chelating Agentsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu